Oropharyngeal Squamous Cell Carcinoma Clinical Trial
Official title:
The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan
NCT number | NCT05522881 |
Other study ID # | T1322 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | November 25, 2022 |
Est. completion date | December 30, 2029 |
We will use the next-generation sequencing (NGS) technology to identify genomic alterations of Taiwanese HPV positive and negative oropharyngeal squamous cell carcinoma (OPSCC) for novel biomarker development and the study design of potential clinical trials or translational research.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 30, 2029 |
Est. primary completion date | December 30, 2029 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: 1. Ages 20 and above 2. Pathological reported as squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) 3. Available p16 immunohistochemical staining status 4. Willingness to provide archival or newly obtained tumor tissues for current study proposal 5. Life expectancy more than 3 months 6. Patients fully understand the protocol with the willingness to have regular follow-up Exclusion criteria 1. Inability to cooperate by providing a complete medical history 2. No available tumor tissues for genetic testing 3. Undesirable compliance 4. Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded |
Country | Name | City | State |
---|---|---|---|
Taiwan | Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung | |
Taiwan | Kaohsiung Veterans General Hospital | Kaohsiung | |
Taiwan | China Medical University Hospital | Taichung | |
Taiwan | Taichung Veterans General Hospital | Taichung | |
Taiwan | National Cheng Kung University Hospital | Tainan | |
Taiwan | Pei-Jen Alex Lou | Taipei | |
Taiwan | Taipei Veterans General Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Health Research Institutes, Taiwan | China Medical University Hospital, Kaohsiung Veterans General Hospital., National Cheng-Kung University Hospital, National Taiwan University Hospital, Taichung Veterans General Hospital, Taipei Veterans General Hospital, Taiwan |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To enroll a total of 300 patients with OPSCC who fit the criteria of this study in the enrolled period | To enroll a total of 300 patients with OPSCC who fit the criteria of this study in the enrolled period | 5 years of proposed observation period | |
Secondary | To perform next generation sequencing analysis of OPSCC tumor tissues | To perform next generation sequencing analysis of OPSCC tumor tissues | 5 years of proposed observation period | |
Secondary | Collect clinical data of OPSCC | To correlate with the clinical characteristics and treatment outcomes of patients with the genetic profile in Taiwan. | 5 years of proposed observation period | |
Secondary | To compare the difference of the genetic and molecular profiles among patients with HPV positive and negative OPSCC | To compare the difference of the genetic and molecular profiles among patients with HPV positive and negative OPSCC | 5 years of proposed observation period | |
Secondary | To compare the difference of genetic and molecular profiles between early (stage I and II) and advanced stage (stage III and IV) of HPV positive OPSCC | To compare the difference of genetic and molecular profiles between early (stage I and II) and advanced stage (stage III and IV) of HPV positive OPSCC | 5 years of proposed observation period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06174428 -
Validity of Viome's Oral/Throat Cancer Test
|
||
Recruiting |
NCT05098119 -
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
|
Phase 2 | |
Suspended |
NCT03952585 -
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03618134 -
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
|
Phase 1/Phase 2 | |
Recruiting |
NCT03421470 -
Docetaxel and Radiation Therapy in Treating Patients With HPV Positive Oropharynx Cancer
|
Phase 3 | |
Completed |
NCT06314711 -
Ex Vivo 3D-ultrasound for Oropharyngeal Cancer
|
N/A | |
Completed |
NCT04572100 -
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06055868 -
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
|
||
Recruiting |
NCT04222543 -
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging
|
Phase 2 | |
Recruiting |
NCT04564989 -
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
|
||
Active, not recruiting |
NCT04965792 -
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
|
||
Recruiting |
NCT06356272 -
Oropharynx (OPX) Biomarker Trial
|
||
Active, not recruiting |
NCT01874171 -
Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC
|
Phase 3 | |
Recruiting |
NCT05333523 -
Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.
|
Phase 3 | |
Completed |
NCT03618654 -
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
|
Early Phase 1 | |
Recruiting |
NCT04801472 -
Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)
|
N/A | |
Active, not recruiting |
NCT03410615 -
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
|
Phase 2 | |
Recruiting |
NCT05268614 -
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05582590 -
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
|
Phase 1 | |
Completed |
NCT02072148 -
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
|
N/A |